FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3082019296> ?p ?o ?g. }

• W3082019296 endingPage "67" @default.
• W3082019296 startingPage "61" @default.
• W3082019296 abstract "Lancovutide activates a chloride channel (TMEM-16A) other than the cystic fibrosis (CF) transmembrane conductance regulator protein and could benefit CF patients.In this randomized, multi-center, double-blind, placebo-controlled, parallel-group trial 161 patients ≥12 years with a confirmed diagnosis of CF were randomized to either placebo (saline) or active drug in 3 different dosing schemes of 2.5mg inhaled lancovutide (once daily, every other day or twice a week) for eight weeks. The primary endpoint was the change in the forced expiratory volume in 1 second (FEV1) percent predicted. Secondary endpoints included further lung function parameters (FEV1 (absolute), functional vital capacity percent predicted, forced expiratory flow percent predicted, pulse oximetry), quality of life assessment, pulmonary exacerbations, hospitalization due to pulmonary exacerbations, time to first pulmonary exacerbation, duration of anti-inflammatory, mucolytic or antibiotic treatment, and safety.There was no significant difference in the change in FEV1 percent predicted, quality of life, other lung function parameters, pulmonary exacerbations or requirement of additional treatment between groups. Overall, the inhalation of lancovutide was safe although a higher rate of adverse events, especially related to the respiratory system, occurred as compared to placebo.Lancovutide did not improve FEV1 percent predicted when compared to placebo (NCT00671736)." @default.
• W3082019296 created "2020-09-08" @default.
• W3082019296 creator A5000776896 @default.
• W3082019296 creator A5017024281 @default.
• W3082019296 creator A5022682741 @default.
• W3082019296 creator A5029730706 @default.
• W3082019296 creator A5036082730 @default.
• W3082019296 creator A5040269214 @default.
• W3082019296 creator A5046162707 @default.
• W3082019296 creator A5051431720 @default.
• W3082019296 creator A5069537591 @default.
• W3082019296 creator A5077190197 @default.
• W3082019296 creator A5078397999 @default.
• W3082019296 creator A5080941679 @default.
• W3082019296 date "2021-01-01" @default.
• W3082019296 modified "2023-09-26" @default.
• W3082019296 title "Aerosolized lancovutide in adolescents (≥12 years) and adults with cystic fibrosis – a randomized trial" @default.
• W3082019296 cites W1513713646 @default.
• W3082019296 cites W1589654967 @default.
• W3082019296 cites W1990858610 @default.
• W3082019296 cites W2002368150 @default.
• W3082019296 cites W2036946013 @default.
• W3082019296 cites W2074901077 @default.
• W3082019296 cites W2076739918 @default.
• W3082019296 cites W2090648579 @default.
• W3082019296 cites W2095025627 @default.
• W3082019296 cites W2119872663 @default.
• W3082019296 cites W2125078269 @default.
• W3082019296 cites W2131295433 @default.
• W3082019296 cites W2140868856 @default.
• W3082019296 cites W2144755740 @default.
• W3082019296 cites W2155231569 @default.
• W3082019296 cites W2159671628 @default.
• W3082019296 cites W2170130419 @default.
• W3082019296 cites W2905868380 @default.
• W3082019296 cites W2912042923 @default.
• W3082019296 cites W2982296199 @default.
• W3082019296 cites W2985405196 @default.
• W3082019296 cites W2997818179 @default.
• W3082019296 cites W3015728615 @default.
• W3082019296 cites W3049341660 @default.
• W3082019296 doi "https://doi.org/10.1016/j.jcf.2020.08.014" @default.
• W3082019296 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32888826" @default.
• W3082019296 hasPublicationYear "2021" @default.
• W3082019296 type Work @default.
• W3082019296 sameAs 3082019296 @default.
• W3082019296 citedByCount "3" @default.
• W3082019296 countsByYear W30820192962021 @default.
• W3082019296 countsByYear W30820192962022 @default.
• W3082019296 crossrefType "journal-article" @default.
• W3082019296 hasAuthorship W3082019296A5000776896 @default.
• W3082019296 hasAuthorship W3082019296A5017024281 @default.
• W3082019296 hasAuthorship W3082019296A5022682741 @default.
• W3082019296 hasAuthorship W3082019296A5029730706 @default.
• W3082019296 hasAuthorship W3082019296A5036082730 @default.
• W3082019296 hasAuthorship W3082019296A5040269214 @default.
• W3082019296 hasAuthorship W3082019296A5046162707 @default.
• W3082019296 hasAuthorship W3082019296A5051431720 @default.
• W3082019296 hasAuthorship W3082019296A5069537591 @default.
• W3082019296 hasAuthorship W3082019296A5077190197 @default.
• W3082019296 hasAuthorship W3082019296A5078397999 @default.
• W3082019296 hasAuthorship W3082019296A5080941679 @default.
• W3082019296 hasBestOaLocation W30820192961 @default.
• W3082019296 hasConcept C126322002 @default.
• W3082019296 hasConcept C142724271 @default.
• W3082019296 hasConcept C165637977 @default.
• W3082019296 hasConcept C168563851 @default.
• W3082019296 hasConcept C197934379 @default.
• W3082019296 hasConcept C203092338 @default.
• W3082019296 hasConcept C204787440 @default.
• W3082019296 hasConcept C27081682 @default.
• W3082019296 hasConcept C2776042228 @default.
• W3082019296 hasConcept C2776938444 @default.
• W3082019296 hasConcept C2776954882 @default.
• W3082019296 hasConcept C2777014857 @default.
• W3082019296 hasConcept C2777637488 @default.
• W3082019296 hasConcept C2777714996 @default.
• W3082019296 hasConcept C2778974779 @default.
• W3082019296 hasConcept C2780333948 @default.
• W3082019296 hasConcept C3018587741 @default.
• W3082019296 hasConcept C42219234 @default.
• W3082019296 hasConcept C523546767 @default.
• W3082019296 hasConcept C54355233 @default.
• W3082019296 hasConcept C55520419 @default.
• W3082019296 hasConcept C71924100 @default.
• W3082019296 hasConcept C75603125 @default.
• W3082019296 hasConcept C86803240 @default.
• W3082019296 hasConceptScore W3082019296C126322002 @default.
• W3082019296 hasConceptScore W3082019296C142724271 @default.
• W3082019296 hasConceptScore W3082019296C165637977 @default.
• W3082019296 hasConceptScore W3082019296C168563851 @default.
• W3082019296 hasConceptScore W3082019296C197934379 @default.
• W3082019296 hasConceptScore W3082019296C203092338 @default.
• W3082019296 hasConceptScore W3082019296C204787440 @default.
• W3082019296 hasConceptScore W3082019296C27081682 @default.
• W3082019296 hasConceptScore W3082019296C2776042228 @default.
• W3082019296 hasConceptScore W3082019296C2776938444 @default.
• W3082019296 hasConceptScore W3082019296C2776954882 @default.

• next